THE MATTSON JACK GROUP RELEASES COMORBIDITY DATABASE.

The Mattson Jack Group, Inc. (MattsonJack), St. Louis, has released its Comorbidity Database(TM). Comorbidity Database(TM) is designed to help clients make strategic decisions based on an in-depth understanding of the importance of mutually exclusive and overlapping conditions. Comorbidity Database(TM) consists of two modules: Comorbidity Database(TM) -- CNS 2.0, which focuses on mental health disorders, and Comorbidity Database(TM) -- Med 2.0, which features a broad range of medical diagnoses and risk factors, excluding mental health disorders.

The Comorbidity Database(TM) will provide patient numbers for mutually exclusive segments for any combination of disorders / diagnostic categories. "Pharmaceutical companies can use this information to build accurate market forecasts, identify patient subgroups by various risk factors, and analyze overlaps of subgroup populations," said David Robinson, Director of Epidemiology at MattsonJack.

The Comorbidity Database(TM) product offerings exemplify MattsonJack's commitment to epidemiology and continuous product enhancement. Additional information on disorders or conditions covered by each module, data sources, and additional enhancements can be found on MattsonJack's website: Comorbidity Database(TM). To arrange a personal demonstration of the Comorbidity Database(TM), e-mail Deborah Hammonds, or telephone 314.529.3064.

About The Mattson Jack Group, Inc. (http://www.mattsonjack.com/)

Formed in 1986, MattsonJack focuses its client support in three areas of Competency: Business Analytics, Brand Optimization, and Corporate Development services in the pharmaceutical and biotech markets.

MattsonJack's knowledgeware and client productivity tools include Epi Database(R) and Forecast Architect(R). Additionally, MattsonJack, as one of the largest global oncology consulting firms, supports its clients' cancer interests through its MattsonJack DaVinci multiclient offerings, including CancerMPact(R), Oncology Marketing Strategies(TM), Supportive Care Perspectives(TM), and its Future Focus(TM) series Myelodysplastic Syndromes (MDS) and Gastrointestinal Stromal Tumor (GIST).

MattsonJack consultants have expertise in pricing and reimbursement, custom epidemiology, technology assessment, business and strategic plan development, due diligence and licensing support, market modeling and forecasting, and primary market research. MattsonJack's client list ranges from emerging companies to some of the most recognized pharmaceutical and biotech companies in the world, such as Abbott, Amgen, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson Companies, Merck, Novartis, Pfizer, Roche, Wyeth, and many others. MattsonJack is part of Kantar Group, the Information and Consultancy division of WPP, a $10+ billion global communications services firm.

For more information, visit http://www.mattsonjack.com or call 314/529-3034.

About Kantar Group

Kantar is one of the world's largest research, insight, and consultancy networks. It helps clients make better business decisions through a deeper understanding of their markets, their brands, and their customers. Part of WPP, Kantar brings together a diverse group of outstanding marketing insight and consulting companies -- each an expert in their field who can work together seamlessly to help clients address business issues in a holistic and strategic way.

For more information, visit http://www.kantargroup.com.

Companies include Added Value Group, IMRB, BMRB, BPRI, Cannondale Associates, Center Partners, Everystone, Focalyst, Fusion 5, Glendinning Management Consultants, Henley Centre HeadlightVision, IMRB, Kantar Operations, KMR Group, Lightspeed Research, Management Ventures, MattsonJack Group, Millward Brown, Research International, RMS and Ziment Group. The group operates in more than 160 offices across 60 markets worldwide.